KOSELUGO
Total Payments
$16.7M
Transactions
2,260
Doctors
920
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.6M | 878 | 460 |
| 2023 | $3.3M | 816 | 450 |
| 2022 | $4.7M | 285 | 121 |
| 2021 | $4.9M | 163 | 77 |
| 2020 | $2.1M | 118 | 55 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $15.3M | 84 | 91.8% |
| Consulting Fee | $790,508 | 324 | 4.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $401,130 | 172 | 2.4% |
| Travel and Lodging | $108,327 | 313 | 0.7% |
| Food and Beverage | $68,709 | 1,363 | 0.4% |
| Space rental or facility fees (teaching hospital only) | $5,500 | 2 | 0.0% |
| Education | $29.70 | 2 | 0.0% |
Payments by Type
Research
$15.3M
84 transactions
General
$1.4M
2,176 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AZD6244 NCI Programme | AstraZeneca Pharmaceuticals LP | $6.0M | 0 |
| Phase II Trial of Immunotherapy with MEDI4736 With Continuous or Intermittent MEK Inhibitor Selumetinib in KRAS Mutant NSCLC | AstraZeneca Pharmaceuticals LP | $2.0M | 0 |
| Phase I trial of the mitogen activated protein kinase (MEK) 1 inhibitor AZD6244 in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN) | AstraZeneca Pharmaceuticals LP | $1.7M | 0 |
| Phase 2 trial of the MEK inhibitor selumetinib in combination with the dual mTOR kinase inhibitor AZD2014 for patients with unresectable or metastatic malignant peripheral nerve sheath tumors MPNST | AstraZeneca Pharmaceuticals LP | $1.5M | 0 |
| A Phase 3 Randomized Study of Selumetinib versus Carboplatin Vincristine in Children with Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 NF1 associated Low Grade Glioma LGG | AstraZeneca Pharmaceuticals LP | $1.1M | 0 |
| Retrospective Analysis of LGG indication for Koselugo including Treatment and Re-Treatment of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma | AstraZeneca UK Limited | $842,676 | 0 |
| Phase 2 trial of selumetinib in patients with Neurofibromatosis type II related tumors | AstraZeneca Pharmaceuticals LP | $571,596 | 0 |
| A Phase III, Multicentre, International Study with a Parallel, Randomized, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Patients with NF1 and Symptomatic Inoperable Plexiform Neurofibromas (KOMET) | AstraZeneca Pharmaceuticals LP | $417,162 | 0 |
| A Phase I II, Single-Arm, Open-label Study to Evaluate the Pharmacokinetics, Safety Tolerability and Efficacyof the Selumetinib Granule Formulation in Children Aged | AstraZeneca Pharmaceuticals LP | $363,357 | 0 |
| Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Toxicity of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas | AstraZeneca Pharmaceuticals LP | $243,319 | 0 |
| Multi Center Phase Ib Study of Intermittent Dosing of the MEK inhibitor Selumetinib in Patients with advanced Uveal Melanoma Not Previously Treated with a MEK Inhibitor | AstraZeneca Pharmaceuticals LP | $199,108 | 0 |
| A Randomized Open Label Phase I Trial of Continuous Intermittent and Pulsatile Selumetinib AZD6244 plus nab-Paclitaxel as Second Line Treatment for Stage IIIB or IV Non Small Cell Lung Cancer NSCLC | AstraZeneca Pharmaceuticals LP | $112,652 | 0 |
| Phase I trial of the mitogen activated protein kinase (MEK) 1 inhibitor AZD6244 in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN) | AstraZeneca UK Limited | $56,455 | 0 |
| Phase I Study of MEK Inhibitor Selumentinib in Combination with Azacitidine in Patients with Higher Risk Chronic Myeloid Neoplasia- MDS, MDS MPNs and Myelofibrosis | AstraZeneca Pharmaceuticals LP | $35,035 | 0 |
| Title not available in IMPACT or MLCS description not available at AZ Clinical Trials | AstraZeneca Pharmaceuticals LP | $21,589 | 0 |
| RU241306I Randomized Double Blind Phase II Study of Radioactive Iodine RAI in Combination with Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent Metastatic Thyroild Cancers | AstraZeneca Pharmaceuticals LP | $19,513 | 0 |
| TA description Oncology Product Koselugo Indications Pilocytic Astrocytoma Phase descripton Phase 1 | AstraZeneca UK Limited | $15,680 | 0 |
| Koselugo AZD6244, ARRY-142886 | AstraZeneca Pharmaceuticals LP | $13,000 | 0 |
| \";A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD6244 Hyd-Sulfate When Given in Combination with Standard Doses of Selected Chemotherapies to Patients with Advanced Solid Tumors\"; | AstraZeneca Pharmaceuticals LP | $7,000 | 0 |
| Assess Efficacy and Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for vKiras2 Kirsten Rat Sarcoma Viral Oncogene Homolog KRAS Positive NSCLC | AstraZeneca Pharmaceuticals LP | $6,043 | 0 |
Top Doctors Receiving Payments for KOSELUGO
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Portland, OR | $15.3M | 88 |
| , M.D | Neurology | Houston, TX | $84,865 | 109 |
| , RN MSN CPNP | Pediatrics | Los Angeles, CA | $70,039 | 109 |
| , MD, MPH | Pediatric Hematology-Oncology | Fort Worth, TX | $64,237 | 50 |
| , M.D | Neurology with Special Qualifications in Child Neurology | San Francisco, CA | $55,313 | 44 |
| , MD | Pediatric Hematology-Oncology | Washington, DC | $55,136 | 27 |
| , M.D | Pediatrics | New York, NY | $49,601 | 50 |
| , D.O | Pediatric Hematology-Oncology | Madera, CA | $47,627 | 37 |
| , MD | Pediatric Hematology-Oncology | Detroit, MI | $44,775 | 37 |
| , MD | Pediatric Hematology-Oncology | Chicago, IL | $42,955 | 18 |
| , M.D | Clinical Genetics (M.D.) | New Orleans, LA | $39,970 | 59 |
| , M.D | Pediatrics | Pittsburgh, PA | $38,793 | 28 |
| Michael Mangum | Pediatrics | Phoenix, AZ | $37,693 | 41 |
| , MD PHD MPH | Medical Oncology | Phoenix, AZ | $30,306 | 18 |
| , MD | Pediatric Hematology-Oncology | Minneapolis, MN | $29,429 | 32 |
| , MD | Neurology | Wilmington, DE | $27,475 | 13 |
| , M.D | Pediatric Hematology-Oncology | Cleveland, OH | $26,715 | 24 |
| , M.D | Neurological Surgery | Saint Petersburg, FL | $25,470 | 3 |
| Kevin Bielamowicz | Pediatric Hematology-Oncology | Little Rock, AR | $23,769 | 19 |
| , MD | Pediatric Hematology-Oncology | Richmond, VA | $22,556 | 11 |
| , M.D., MPH | Pediatric Hematology-Oncology | Chicago, IL | $20,577 | 15 |
| , MD | Clinical Genetics (M.D.) | Salt Lake City, UT | $19,739 | 10 |
| , M.D | Clinical Genetics (M.D.) | Rochester, MN | $16,461 | 16 |
| , MD | Neurology | Baltimore, MD | $16,186 | 10 |
| , M.D | Pediatrics | Philadelphia, PA | $16,029 | 3 |
Ad
Manufacturing Companies
- AstraZeneca Pharmaceuticals LP $14.8M
- Alexion Pharmaceuticals, Inc. $962,650
- AstraZeneca UK Limited $919,125
Product Information
- Type Drug
- Total Payments $16.7M
- Total Doctors 920
- Transactions 2,260
About KOSELUGO
KOSELUGO is a drug associated with $16.7M in payments to 920 healthcare providers, recorded across 2,260 transactions in the CMS Open Payments database. The primary manufacturer is AstraZeneca Pharmaceuticals LP.
Payment data is available from 2020 to 2024. In 2024, $1.6M was paid across 878 transactions to 460 doctors.
The most common payment nature for KOSELUGO is "Unspecified" ($15.3M, 91.8% of total).
KOSELUGO is associated with 20 research studies, including "AZD6244 NCI Programme" ($6.0M).